Laboratory Studies
A complete blood count is performed to assess the degree of anemia, thrombocytopenia, and neutropenia or leukocytosis. If these measurements are low, supportive treatments may be given or precautionary measures may be initiated. A peripheral blood smear to look for circulating leukemic cells and to assess for disseminated intravascular coagulation should be performed.
Chemistry profile is necessary to assess baseline levels for BUN and creatinine prior to initiation of chemotherapy and to monitor these levels during chemotherapy as a reflection of renal function. Most patients with leukemia have an elevated lactic dehydrogenase (LDH) level and an elevated uric acid level. Elevation of LDH is often a poor prognostic sign.
Liver function tests and BUN and creatinine determinations are necessary prior to the initiation of therapy because many chemotherapeutic agents may adversely affect either renal function or hepatic function. Additionally, some agents, such as methotrexate, may be contraindicated in individuals with hepatic dysfunction.
Some leukemias may have other electrolyte abnormalities, including hypokalemia, hypocalcemia, and/or hypomagnesemia. In adult T-cell leukemia/lymphoma (ATLL), hypercalcemia occurs in approximately one third of all patients.
Appropriate cultures should be obtained in patients with fever or signs of infection.
Imaging Studies
Imaging studies should be obtained based on the patient's symptoms to determine the extent of extramedullary involvement of leukemia or potential sites of infection. Some imaging studies may be needed to assess the baseline status prior to chemotherapy administration; for example, echocardiography may be performed prior to the initiation of chemotherapy.
In all the leukemias, chest radiography may show evidence of an infection, such as pneumonia. In some cases of T-cell acute lymphocytic leukemia (ALL), mediastinal lymphadenopathy may be present.
Typical hepatomegaly and splenomegaly may be imaged by using a liver/spleen scan. Most often, these findings are so obvious in cases of chronic lymphocytic leukemia (CLL), hairy cell leukemia, and ATLL that imaging is unnecessary because the organs are easily palpable. In milder cases, liver or spleen scan or ultrasonography may reveal more subtle organomegaly.
Computed tomography of the chest, the abdomen, or the pelvis is generally not required for staging purposes. However, be careful not to miss lesions, such as obstructive uropathy or airway obstruction, that are caused by lymph node compression on organs or internal structures.
Other Tests
Cytogenetic studies and flow cytometry on peripheral blood may be performed. In cases of ATLL, studies to assess monoclonal integration of the HTLV-I genome into genomic DNA are helpful.
Procedures
Skin biopsy
Skin biopsy with appropriate immunohistochemical staining is the key to diagnosing aleukemic leukemia cutis or identifying leukemia cutis, a sign of extramedullary extension of the leukemia, and a poor prognosis. This diagnosis will likely impact the most appropriate course of treatment.
Bone marrow aspiration and biopsy are the definitive diagnostic tests for the diagnosis of systemic leukemia. Bone marrow aspirates should be stained with either Wright stain or Giemsa stain for morphologic analysis. In addition, slides should be stained with immunocytochemical stains to determine the cell lineage and the degree of maturation. Bone marrow samples should be sent for cytogenetic and flow cytometric studies.
Immunophenotyping
Immunophenotyping of infiltrates with specific markers is a valuable adjunct in confirming the diagnosis of leukemia cutis and in differentiating specific from nonspecific cutaneous infiltrates. Specific markers include the following: CD3 (T cells), CD45RO (mature T cells), CD45/LCA (leukocyte common antigen) (lymphocytes, monocytes), CD43 (T cells, monocytes, and granulocytes), CD20 (B cells), CD30 (activated T cells), CD68 (monocytes), and lysozyme (granulocytes, monocytes) (see Table 2 below).
Table 2. Recommended Immunohistochemical Stains For Leukemia Cutis (Open Table in a new window)
| Cell Lineage | CD Antigen Marker |
| T cell | CD45 (LCA) strongly positive CD45RO usually strongly positive CD3 positive but only scattered |
| B cell | CD20 strongly positive but scattered in normal B cells, weakly positive or negative in abnormal small B cells, positive in abnormal large B cells CD43 usually negative |
| Granulocytes | Lysozyme strongly positive in well and poorly differentiated granulocytes Chloroacetate esterase positive in well-differentiated granulocytes CD68 usually negative in all granulocytes |
| Monocytes | Lysozyme strongly positive in well and poorly differentiated monocytes Chloroacetate esterase usually negative CD68 positive in well-differentiated monocytes |
Chloroacetate esterase stains CML and most subtypes of AML but not AML-M4. However, lysozyme should stain all forms of AML and CML.
AML-M4 types express CD43 and CD68 as well. CD43, CD45, and CD15 are positive in almost all types of AML-M5 and AML-M4.
B-cell CLL cells express B-cell markers, including dimCD20. In T-cell CLL, CD45RO and CD3 are either negative or only weakly positive. ATLL cells stain with CD3, CD4, and CD25. CD8 is most often negative.
Hairy cell leukemia cells, which are of the B-cell lineage, stain strongly with tartrate-resistant acid phosphatase. Hairy cells have a mature B-cell phenotype and express immunoglobulin light chains and B-cell antigens, such as CD19, CD20, and CD22, but not CD21. Monoclonal Bly-7 has a high sensitivity and specificity for hairy cell leukemia. CD22 stains hairy cell leukemia more prominently than normal B cells.
Histologic Findings
The histologic findings in leukemia cutis vary depending on the subtype of leukemia. Typically, little epidermal involvement with an underlying grenz zone is present. A dermal infiltrate of leukemic cells, which is often perivascular and periadnexal, is present. Collagen bundles may be prominently separated by leukemic cells. The leukemic cells may also infiltrate along the fibrous septae of the subcutaneous fat. The cells may be seen in the lumina of the blood vessels as well as infiltrating the walls, producing a leukemic vasculitis.
Cells in AML are large with an oval, vesicular nucleus and basophilic cytoplasm. Note the images below.
Low-power view of leukemia cutis acute myeloblastic leukemia (AML-M1). Note the perivascular and periadnexal infiltrate with relative epidermal sparing. Courtesy of Kim Hiatt, MD.
This is a higher power view of leukemia cutis acute myeloblastic leukemia (AML-M1). This photo illustrates a perivascular infiltrate of leukemic cells. The nuclei are round to oval with little cytoplasm. Courtesy of Kim Hiatt, MD. In CML, a variety of cells at varying degrees of maturation are present. Eosinophils may be present. Note the image below.
Leukemia cutis of acute monocytic leukemia. Perivascular and periadnexal infiltration is also present, but the cell morphology is distinct. Many of the nuclei are folded or indented. The cytoplasm of the leukemic cells is gray-blue and more abundant than in the M1 subtype. Courtesy of Kim Hiatt, MD. ALL shows medium-to-large blast cells, with a high nuclear-to-cytoplasmic ratio.
CLL shows small, more uniform, mature lymphocytes. These have dense nuclear chromatin. T-cell CLL may show epidermotropism, as do other T-cell leukemias.
Monocytic leukemia may be confused with large cell lymphoma because of the large nucleus with fine chromatin and prominent nucleoli. The nuclei are often indented or kidney shaped and slightly basophilic in appearance. Monocytic leukemia often involves the entire dermis and the superficial panniculus.
ATLL cells show an indented to lobulated nucleus, which has led to the term flower cells to describe the morphology. ATLL unlike many of the other leukemic infiltrates often shows epidermotropism. Pautrier microabscesses, as can be seen in mycosis fungoides, may be present.
Hairy cell leukemia, like many other forms of leukemia cutis, infiltrates the dermis and the subcutaneous fat. It too shows prominent periadnexal and perivascular infiltration. The infiltrate consists of monomorphous mononuclear cells. A grenz zone is typically present. Note the images below.
Low-power view of acute promyelocytic leukemia cutis with a perivascular and periadnexal but also interstitial infiltrate, with epidermal sparing but significant upper dermal edema, which could be confused with Sweet syndrome at a low-power view. Courtesy of Kim Hiatt, MD.
Photo illustrates leukocyte esterase staining of the cytoplasm of the leukemic cells in acute promyelocytic leukemia. Courtesy of Kim Hiatt, MD.
Photo illustrates leukocyte esterase staining of the cytoplasm of the leukemic cells in acute promyelocytic leukemia. Courtesy of Kim Hiatt, MD.
Leukemia cutis at low power demonstrating a Grenz zone and intercalation of leukemic cells between collagen bundles. Courtesy of Keliegh Culpepper, MD.
A higher-power view of intercalation of leukemic cells between collagen bundles. Courtesy of Keliegh Culpepper, MD. Staging
Staging is extensively discussed in other articles about each of the subtypes of leukemia elsewhere in the eMedicine Journal.
Cho-Vega JH, Medeiros LJ, Prieto VG, Vega F. Leukemia cutis. Am J Clin Pathol. Jan 2008;129(1):130-42. [Medline].
Agis H, Weltermann A, Fonatsch C, et al. A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis. Ann Hematol. Feb 2002;81(2):90-5. [Medline].
Kaddu S, Smolle J, Cerroni L, Kerl H. Prognostic evaluation of specific cutaneous infiltrates in B-chronic lymphocytic leukemia. J Cutan Pathol. Dec 1996;23(6):487-94. [Medline].
Baer MR, Barcos M, Farrell H, Raza A, Preisler HD. Acute myelogenous leukemia with leukemia cutis. Eighteen cases seen between 1969 and 1986. Cancer. Jun 1 1989;63(11):2192-200. [Medline].
Shaikh BS, Frantz E, Lookingbill DP. Histologically proven leukemia cutis carries a poor prognosis in acute nonlymphocytic leukemia. Cutis. Jan 1987;39(1):57-60. [Medline].
Cerroni L, Hofler G, Bck B, Wolf P, Maier G, Kerl H. Specific cutaneous infiltrates of B-cell chronic lymphocytic leukemia (B-CLL) at sites typical for Borrelia burgdorferi infection. J Cutan Pathol. Mar 2002;29(3):142-7. [Medline].
Su WP, Buechner SA, Li CY. Clinicopathologic correlations in leukemia cutis. J Am Acad Dermatol. Jul 1984;11(1):121-8. [Medline].
Jones D, Dorfman DM, Barnhill RL, Granter SR. Leukemic vasculitis: a feature of leukemia cutis in some patients. Am J Clin Pathol. Jun 1997;107(6):637-42. [Medline].
Pranteda G, Gueli N, Innocenzi D. Skin vasculitis with direct vessel infiltration by leukaemic cells: a case report. Acta Derm Venereol. Jun-Jul 2001;81(3):215-6. [Medline].
Smoller BR. Leukemic vasculitis: a newly described pattern of cutaneous involvement. Am J Clin Pathol. Jun 1997;107(6):627-9. [Medline].
Fadilah SA, Alawiyah AA, Amir MA, Cheong SK. Leukaemia cutis presenting as leonine facies. Med J Malaysia. Mar 2003;58(1):102-4. [Medline].
Heskel NS, White CR, Fryberger S, Neerhout RC, Spraker M, Hanifin JM. Aleukemic leukemia cutis: juvenile chronic granulocytic leukemia presenting with figurate cutaneous lesions. J Am Acad Dermatol. Sep 1983;9(3):423-7. [Medline].
Chang HY, Wong KM, Bosenberg M, McKee PH, Haynes HA. Myelogenous leukemia cutis resembling stasis dermatitis. J Am Acad Dermatol. Jul 2003;49(1):128-9. [Medline].
Connelly TJ, Kauh YC, Luscombe HA, Becker G. Leukemic macrocheilitis associated with hairy-cell leukemia and the Melkersson-Rosenthal syndrome. J Am Acad Dermatol. Feb 1986;14(2 Pt 2):353-8. [Medline].
Freiman A, Muhn CY, Trudel M, Billick RC. Leukemia cutis presenting with fingertip hypertrophy. J Cutan Med Surg. Jan-Feb 2003;7(1):57-60. [Medline].
Ikeda T, Sakurane M, Uede K, Furukawa F. A case of symmetrical leukemia cutis on the eyelids complicated by B-cell chronic lymphocytic lymphoma. J Dermatol. Jul 2004;31(7):560-3. [Medline].
Ferreira M, Caetano M, Amorim I, Selores M. Leukemia cutis resembling a flare-up of psoriasis. Dermatol Online J. Mar 30 2006;12(3):13. [Medline].
High DA, Luscombe HA, Kauh YC. Leukemia cutis masquerading as chronic paronychia. Int J Dermatol. Nov 1985;24(9):595-7. [Medline].
Simon CA, Su WP, Li CY. Subungual leukemia cutis. Int J Dermatol. Nov 1990;29(9):636-9. [Medline].
Beynet D, Oro AE. Leukemia cutis presenting as a Sister Mary Joseph nodule. Arch Dermatol. Sep 2004;140(9):1170-1. [Medline].
Watanabe H, Okuyama R, Tagami H, Aiba S. Leukaemia cutis developing in a pressure ulcer. Acta Derm Venereol. 2004;84(5):412-3. [Medline].
Burns CA, Scott GA, Miller CC. Leukemia cutis at the site of trauma in a patient with Burkitt leukemia. Cutis. Jan 2005;75(1):54-6. [Medline].
Weinel S, Malone J, Jain D, Callen JP. Therapy-related leukaemia cutis: a review. Australas J Dermatol. Nov 2008;49(4):187-90. [Medline].
Chao SC, Lee JY, Tsao CJ. Leukemia cutis in acute lymphocytic leukemia masquerading as viral exanthem. J Dermatol. Apr 1999;26(4):216-9. [Medline].
Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. Jul 1 2006;24(19):3187-205. [Medline].
Poiesz BJ, Papsidero LD, Ehrlich G, et al. Prevalence of HTLV-I-associated T-cell lymphoma. Am J Hematol. Jan 2001;66(1):32-8. [Medline].
Roboz GJ, Knovich MA, Bayer RL, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. Leuk Lymphoma. Oct 2002;43(10):1951-5. [Medline].
Schwonzen M, Kuehn N, Vetten B, Diehl V, Pfreundschuh M. Phenotyping of acute myelomonocytic (AMMOL) and monocytic leukemia (AMOL): association of T-cell-related antigens and skin-infiltration in AMOL. Leuk Res. 1989;13(10):893-8. [Medline].
Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. Jul 1 2001;19(13):3244-54. [Medline].
Yoshie O, Fujisawa R, Nakayama T, et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood. Mar 1 2002;99(5):1505-11. [Medline].
| Type of Leukemia | Incidence in the United States | Percentage of Patients with Leukemia Cutis (%) |
| AML | 2.5 cases per 100,000 population | 13 |
| Acute lymphocytic leukemia | 1.3 cases per 100,000 population | 3 |
| Chronic myelogenous leukemia (CML) | 1-2 cases per 100,000 population | 2-8 |
| Chronic lymphocytic leukemia (CLL) | 2.3 cases per 100,000 population | 8 |
| Hairy cell leukemia | 0.6-2.9 cases per 1,000,000 population | 8 |
| Adult T-cell leukemia | Extremely low | 40-70 |
| Cell Lineage | CD Antigen Marker |
| T cell | CD45 (LCA) strongly positive CD45RO usually strongly positive CD3 positive but only scattered |
| B cell | CD20 strongly positive but scattered in normal B cells, weakly positive or negative in abnormal small B cells, positive in abnormal large B cells CD43 usually negative |
| Granulocytes | Lysozyme strongly positive in well and poorly differentiated granulocytes Chloroacetate esterase positive in well-differentiated granulocytes CD68 usually negative in all granulocytes |
| Monocytes | Lysozyme strongly positive in well and poorly differentiated monocytes Chloroacetate esterase usually negative CD68 positive in well-differentiated monocytes |

